



TOPAMAX ▼ (Topiramate): PREGNANCY PREVENTION PROGRAMME

Annual redistribution of Educational Materials

30 July 2026

Dear Healthcare Professional,

Further to the introduction of the **Pregnancy Prevention Programme** for topiramate-containing medicinal products in July 2024, please find enclosed the **educational materials** developed to prevent the risk of topiramate exposure during pregnancy. These materials are being sent to you as a part of the annual redistribution. Please note that there were no changes to the safety information in any of the materials. The scope of this letter is to remind you to always follow the instructions of the Pregnancy Prevention Programme. These materials have been approved by the Health Products Regulatory Authority (HPRA).

Enclosed please find for use in your clinical practice:

- **1 Healthcare Professional Guide** – includes guidance on the actions for healthcare professionals on implementing the Pregnancy Prevention Programme.
- **5 Patient Guides** - this should be used when discussing the risks of exposure to topiramate during pregnancy and be provided to all girls and women of childbearing potential being prescribed topiramate.
- **5 Annual Risk Awareness Forms** – this should be discussed and completed by the doctor with all female patients of childbearing potential treated with topiramate – at treatment initiation (or when menarche is reached), at each annual visit, when a pregnancy is planned or if a pregnancy occurs.
- **1 Patient Card** - pharmacists should ensure a patient card is provided to all female patients of childbearing potential each time topiramate is dispensed. The patient card is now included in the Topamax carton.

Electronic copies of the Patient Guide, Healthcare Professional Guide, Annual Risk Awareness Form and the Patient Card are available on www.medicines.ie and www.topamaxandme.ie. An electronic copy of these educational materials can also be found on the HPRA website at www.hpra.ie (enter 'Topamax' or 'topiramate' in the search box and click on 'EdM' next to any of the medicines that appear). Additional copies of all materials can be requested from Janssen by contacting our medical information team at medinfo@its.jnj.com or by calling Medical Information on 1800 709 122.

Healthcare professionals are reminded that:

- Topiramate can cause major congenital malformations and foetal growth restriction when used during pregnancy. Recent data also suggest a possibly increased risk of neurodevelopmental disorders (NDD) including autism spectrum disorders, intellectual disability and attention deficit hyperactivity disorder (ADHD) following topiramate use during pregnancy.
- Contraindications apply for the treatment of epilepsy:
 - in pregnancy, unless there is no suitable alternative treatment;
 - in women of childbearing potential not using highly effective contraception. The only exception is a woman for whom there is no suitable alternative but who plans a pregnancy and who is fully informed about the risks of taking topiramate during pregnancy.
- Topiramate for prophylaxis of migraine is already contraindicated in pregnancy and in women of childbearing potential not using highly effective contraception.
- Treatment of female children (in the case of epilepsy) and women of childbearing potential (for epilepsy and migraine) should be initiated and supervised by a physician experienced in the management of epilepsy or migraine. The need for treatment should be reassessed at least annually.
- Due to a potential interaction, women using systemic hormonal contraceptives should be advised to also use a barrier method.
- For women of childbearing potential currently using topiramate, the treatment should be reevaluated to ensure that the measures of the pregnancy prevention programme are followed.

Call for reporting

Adverse events should be reported. ▼ This medicinal product is subject to additional monitoring, and it is therefore important to report any suspected adverse events related to this medicinal product. Healthcare professionals are asked to report any suspected adverse events via: HPRA Pharmacovigilance, Website: www.hpra.ie. Adverse events should also be reported to Janssen Sciences Ireland UC a Johnson & Johnson Company on 0044 1494 567447 or at dsafety@its.jnj.com.

Company contact point

If you have further questions, please do not hesitate to contact the Janssen Medical Information department on telephone number: 1800 709 122 or email medinfo@its.jnj.com

Yours sincerely,

Electronically signed by:
Brid Seoighe
Reason: I am approving
this document
Date: Jun 12, 2026
15:13:24 GMT+1

Brid Seoighe

Dr Bríd Seoighe
Medical Director
Janssen Sciences Ireland UC